Stock Events

Stock Events

Vaxart 

$0.5708
258
+$0.01+1.03% Wednesday 19:10

Statistics

Day High
0.5779
Day Low
0.5502
52W High
0.84
52W Low
0.26
Volume
68,796
Avg. Volume
-
Mkt Cap
137.04M
P/E Ratio
3.5
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Oct 12
$12.19
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

30JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.1
-0.06
-0.02
0.02
Expected EPS
-0.03
Actual EPS
N/A

Financials

-233.27%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
57.4MRevenue
-133.9MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VXRT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.46B
Novavax is a direct competitor in the development of vaccines, including those for COVID-19, similar to Vaxart's oral vaccine efforts.
Moderna
MRNA
Mkt Cap19.8B
Moderna is a leader in mRNA vaccine technology, competing in the same space as Vaxart's novel vaccine platform.
Pfizer
PFE
Mkt Cap149.38B
Pfizer, with its COVID-19 vaccine developed in collaboration with BioNTech, competes in the vaccine market, including areas Vaxart is targeting.
BioNTech
BNTX
Mkt Cap22.9B
BioNTech partners with Pfizer on COVID-19 vaccines, directly competing with Vaxart's vaccine development efforts.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson developed a COVID-19 vaccine, competing in the broader vaccine market where Vaxart is also a player.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca competes in the COVID-19 vaccine space, an area where Vaxart is also trying to make an impact with its oral vaccine candidates.
Inovio Pharmaceuticals
INO
Mkt Cap90.5M
Inovio Pharmaceuticals is focused on DNA medicines, including vaccines, making it a competitor in the innovative vaccine technology space like Vaxart.
Sanofi
SNY
Mkt Cap105.92B
Sanofi is a large pharmaceutical company with a broad vaccine portfolio, competing in the same market as Vaxart.
GSK
GSK
Mkt Cap106.31B
GlaxoSmithKline has a significant presence in the vaccine market, making it a competitor to Vaxart in the quest to develop and commercialize vaccines.

About

Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Show more...
CEO
Mr. Steven Lo
Employees
105
Country
United States
ISIN
US92243A2006

Listings

MX
MX
VXRT.MX
MU
DE
NB11.MU
OTC Link
US
VXRT

0 Comments

Share your thoughts

FAQ

What is Vaxart stock price today?▼
The current price of VXRT is $0.57 USD — it has increased by +1.03% in the past 24 hours. Watch Vaxart stock price performance more closely on the chart.
What is Vaxart stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vaxart stocks are traded under the ticker VXRT.
Is Vaxart stock price growing?▼
VXRT stock has fallen by -4.86% compared to the previous week, the month change is a -16.05% fall, over the last year Vaxart has showed a -7.03% decrease.
What is Vaxart market cap?▼
Today Vaxart has the market capitalization of 137.04M
When is the next Vaxart earnings date?▼
Vaxart is going to release the next earnings report on July 30, 2026.
What were Vaxart earnings last quarter?▼
VXRT earnings for the last quarter are 0.02 USD per share, whereas the estimation was 0.02 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vaxart revenue for the last year?▼
Vaxart revenue for the last year amounts to 57.4M USD.
What is Vaxart net income for the last year?▼
VXRT net income for the last year is -133.9M USD.
Does Vaxart pay dividends?▼
Yes, VXRT dividends are paid en. The last dividend per share was 12.19 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Vaxart have?▼
As of June 18, 2026, the company has 105 employees.
In which sector is Vaxart located?▼
Vaxart operates in the Health & Wellness sector.
When did Vaxart complete a stock split?▼
The last stock split for Vaxart was on February 14, 2018 with a ratio of 1:11.
Where is Vaxart headquartered?▼
Vaxart is headquartered in South San Francisco, United States.